Clarke Trafford 4

What Happened Clarke Trafford, a director of Traws Pharma, received an award of 33,435 derivative securities on 2026-03-08. The Form 4 records the acquisition amount as 33,435 at $0.00 and the filing footnote clarifies these are stock options granted under the Issuer’s 2021 Incentive Compensation Plan. The options vest 100% on the first anniversary of the grant. This is a compensation grant (an award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-08 (reported on Form 4 filed 2026-03-10)
• Reported amount: 33,435 derivative securities, recorded at $0.00
• Vesting: 100% vesting on the first anniversary of the grant (per footnote)
• Shares owned after transaction: Not disclosed in the Form 4
• Footnote: Awards made by the compensation committee (independent directors) under the 2021 Incentive Compensation Plan
• Filing timeliness: Filed two days after the grant date (no indication of a late filing)

Context This was an option award as part of director compensation, not an exercise or sale; no immediate cash proceeds or share sales occurred. Such grants are commonly used to align a director’s long-term incentives with shareholders; because the options vest in one year, they are not exercisable (for beneficial ownership purposes) until after vesting. As always, awards reflect compensation policy rather than a direct market signal.